Extended IBTROZI follow up highlights durable clinical response Safety profile remains consistent across treated patient ...
SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates ...
Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.
Retrospective, single-center design and limited power render findings hypothesis-generating, supporting prospective ...
The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
When Dan Hannon, 72, received guidance to have part of a lung taken out whether nodules were cancerous or not, he wanted a ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
With the advancement of imaging technologies, the application of 18 F-FDG PET/CT in the diagnosis and management of cervical cancer has garnered increasing attention. This article aims to review the ...
LUND, SE / ACCESS Newswire / March 18, 2026 / Cantargia (STO:CANTA) today reported the presentation of new pre-clinical data ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results